VA Ann Arbor Healthcare System
Prostate Treatment Options for Veterans Expand
VA Ann Arbor Healthcare System is proud to introduce a powerful new magnetic resonance imaging (MRI)-guided solution for targeted biopsy of the prostate. Through our recent adoption of the UroNav™ fusion biopsy system and cross-disciplinary planning efforts, we now offer a cutting-edge biopsy option for many patients with elevated and/or rising PSA levels raising concerns for prostate cancer.
Targeted MRI/ultrasound biopsy is poised to become the new standard in prostate cancer early detection, and the VA Ann Arbor Healthcare system is pleased to be one of the first urology groups in the area to offer this powerful solution to our patients. UroNav™ fuses pre-biopsy MRI images of the prostate with real-time ultrasound resulting in a precise and highly accurate sampling of lesion suspicious for cancer. According to lead radiologist for this project, Dr. Shadi Azar, “Our radiology team at VA Ann Arbor is dedicated to making this integration of advanced imaging and clinical medicine a reality for our patients and those across the state.”
Conventional prostate biopsy is performed randomly and without directing sampling to a specific suspicious area. Fusion biopsy allows targeted sampling to areas of greatest concern improving the diagnosis of prostate cancers that require treatment. After a patient has undergone a prostate MRI, our radiology partners utilize DynaCAD for Prostate™ to quickly visualize and evaluate suspicious lesions. Our UroNav™ fusion biopsy system uses this critical diagnostic information to provide our skilled urologists with a targeted approach to prostate biopsy. The fusion of MRI and ultrasound images through UroNav™ gives our urologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis especially after a routine prostate biopsy fails to detect an underlying cancer.
“This new technology will provide our Veterans and their healthcare providers with state-of-the-art ability to identify and target suspicious prostate lesions and maximize the value of prostate biopsy,” explains Dr. Arvin George, the National Cancer Institute-trained urologic oncologist at VA Ann Arbor Healthcare System who spearheaded acquisition and rollout of the new technology. “Offering this technology to Veterans with suspected prostate cancer across Michigan through support of the VA’s Michigan Market collaborative brings substantial value to these men when they ChooseVA*,” states Dr. Ted Skolarus, Urology Section Chief at VA Ann Arbor Healthcare System.
Other than skin cancer, prostate cancer is most common form of cancer in American men and the second-leading cause of cancer death in this population and the only solid organ cancer sampled with a non-targeted approach until now.† With a global shift towards maximizing the value of prostate biopsy and minimizing overdetection of low risk, slow growing prostate cancer, the VA Ann Arbor Healthcare System’s introduction of MRI/ultrasound fusion biopsy could not have come at a more opportune time.
For more information about the VA Ann Arbor Healthcare System and MRI/ultrasound fusion, visit us on the web at https://www.annarbor.va.gov/services/Urology.asp
*https://www.choose.va.gov; †American Cancer Society (www.cancer.org)